Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Ipilimumab as adjuvant therapy improves OS in high risk melanoma

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.16
Views: 3188

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Prof Eggermont speaks with ecancertv at ESMO 2016 about results from the EORTC 18071 phase III trial of ipilimumab, an anti-CTLA 4 immune checkpoint inhibitor, as an adjuvant therapy for patients with high risk stage III melanoma.

Prof Eggermont describes the improved overall survival rate of five years, 11% high in the ipilumumab arm, as coming at the cost of immune related side effects associated with ipilimumab.

The results were published simultaneously to the conference in the New England Journal of Medicine.

Watch the press conference video or read the news story for more.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation